HD-OPM Archive
Topics › Aging & longevity

Rapamycin for 8 weeks improved diastolic and endothelial function in six older men

Gokhan Can · Oct 31, 2025 · ♥ 7 reactions · 2 comments · original Facebook post
Aging & longevityHeart rhythm & heart failureBlood vessels, circulation & endothelium
AI summary & key facts

Summarises a proof-of-concept open-label pilot in six healthy men aged 70-76 taking rapamycin 1 mg daily for 8 weeks. It was safe and well tolerated; systolic function was unchanged but cardiac MRI showed better diastolic function (peak filling rate p=0.014) and endothelial function improved (p=0.020). Very small and uncontrolled; larger placebo-controlled trials are needed.

Rapamycin for Heart Failure

This proof-of-concept pilot study investigated the effects of rapamycin (RAPA) on cardiovascular function in six healthy men, aged 70–76. Participants were administered 1 mg of RAPA daily for 8 weeks in an open-label trial. The study found the treatment to be safe and well-tolerated. While most measures of systolic function, such as ejection fraction ($p=0.75$), did not change significantly, cardiac MRI revealed statistically significant improvements in key parameters of diastolic function. Specifically, researchers observed an improved peak left-ventricular filling rate ($p=0.014$), increased maximum local blood acceleration ($p=0.004$), and greater total transmitral forward blood volume ($p=0.033$). Additionally, endothelial function, measured by local thermal hyperemic response, showed a significant improvement at the 8-week mark ($p=0.020$). The authors conclude that these findings demonstrate RAPA's potential to ameliorate age-related diastolic and endothelial dysfunction, supporting the need for larger, placebo-controlled clinical trials.

Paper · GeroScience · 2025Short-term mTOR inhibition by rapamycin improves cardiac and endothelial function in older men: a proof-of concept pilot studyRapamycin (RAPA) and related mTOR-inhibitors have been shown to enhance healthy aging in animal models (2–10) and to be generally safe and tolerable in older people (11–13). However, studies to assess their effects on specific age-related pathologies in humans are limited. Since improvements in cardiovascular function with RAPA treatment have been reported in preclinical studies (5, 9, 10, 14–17), we posited that…link.springer.com

Research cited

#rapamycin#endothelialfunction#heartfailure#cardiovascular
← newer: Life expectancy has risen at all ages, not just from fewer colder: BMJ trial: stem cells after heart attack lowered heart failu →